BLASUBCUTANEOUSINJECTABLE
Approved
Oct 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
3/8 — Basic
OSVYRTI (denosumab-desu) by Accord Biopharma is rankl, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption, thereby modulating calcium release from bone. Approved for osteoporosis, postmenopausal osteoporosis, low bone mineral density. First approved in 2025.
Drug data last refreshed Yesterday
Mechanism of Action
RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption, thereby modulating calcium release from bone. Increased osteoclast activity, stimulated by RANKL, is a mediator of bone pathology in solid tumors…
Indications (3)
Worked on OSVYRTI at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.